The Weekly Mind Reader: Early Treatment with LAI Antipsychotics

A new study in The Journal of Clinical Psychiatry compared the effectiveness and safety of two treatment options for individuals with schizophrenia: paliperidone palmitate, a long-acting injectable (LAI) antipsychotic, and oral antipsychotics. The study aimed to assess the benefits of initiating treatment with paliperidone palmitate earlier in the course of the illness.

Key Findings and Implications

The researchers conducted a thorough analysis using data from the PRIDE, PROSIPAL, and DREaM trials. They examined various aspects of each treatment protocols, including how effective it was and whether it was safe. Additionally, they measured various factors including relapse rates, daily function, treatment satisfaction, and any new problems that arose during treatment. 

Treatment failure was defined as relapses leading to psychiatric hospitalizations, legal issues, self-harm or harm to others, discontinuation of medication due to ineffectiveness or safety concerns, the need for additional treatment, and significant worsening of symptoms.

The study revealed promising results to support the use of paliperidone palmitate sooner. Compared to oral antipsychotics, patients treated with the LAI endured fewer instances of treatment failure or relapse, irrespective of the duration of illness. They also had a significantly longer period until their first treatment failure, which suggests that initiating paliperidone palmitate early on may help prevent relapses. 

The researchers identified no new safety concerns with paliperidone palmitate, indicating that it was well-tolerated. In fact, side effects were comparable between the two groups.

However, the researchers did point out a few limitations to their work. Basing an analysis on existing data may have inherent constraints and biases, especially considering that some of the trials were sponsored by the drug’s manufacturer. They also emphasized the importance of approaching schizophrenia as a complex disorder. Treatment responses can vary among individuals. It’s possible that the study’s findings may not be universally applicable.

Limitations aside, the study provided some solid evidence for initiating paliperidone palmitate in the early stages of schizophrenia. Its findings indicate that initiating the use of LAI antipsychotics sooner could lead to improved long-term health outcomes for people with schizophrenia. By preventing relapses and ensuring consistent medication delivery, they may contribute to better symptom control and functional recovery.

IN OTHER PSYCHIATRY AND NEUROLOGY NEWS

• A new investigation looks into the association between dual orexin receptor antagonists and suicide ideation/behavior using real-world data. 
• The effectiveness of rTMS for symptom reduction in depression, schizophrenia, and OCD is associated with differences in neuropathology, disease-specific target site, and frequency of treatment. 
• A patient insisted on documenting her catatonia, ultimately determined to be NMDAr encephalitis, to help clinicians make an earlier diagnosis. This new study includes her video.
• For better or worse, empaths really feel your pain.
• This doc makes a great point: When you talk about suicide, the words you choose matter.

 

View this post on Instagram

 

A post shared by Kali Hobson, MD (@drkalimd)

NEW AT CME INSTITUTE

Get early access and a special rate to Emerging Perspectives in Neurology, a live CME meeting in San Clemente, CA on December 1.